Standard vs. targeted oxygen therapy prehospitally for chronic obstructive pulmonary disease (STOP-COPD): study protocol for a randomised controlled trial.

"Declarations Ethics approval and consent to participate {24}The trial was approved by the Danish Medicinal Research Ethical Committee and the Danish Medicinal Agency (EUCT number: 2022-502003-30-00) Search for clinical trials - EMA (euclinicaltrials.eu). Written, informed consent to participate will be obtained on all patients from patients, surrogates, or legal guardians. Consent for publication {32}The consent form (in Danish) and participant information material (in Danish) are available as supplemental document 2. Competing interests {28}The authors declare that they have no competing interests. Competing interests {28} The authors declare that they have no competing interests."

"Funding {4} The STOP-COPD trial received support from the following private and governmental foundations and/or institutions (names in Danish and English): Den Landsdækkende Akutlægehelikopterordning (English language: “Danish Air Ambulance”), Simon Spies Fonden (English language “the Simon Spies Foundation”), Eva Merete Crone Falck’s Fond (English language “the Eva Merete Crone Falck’s Foundation”, funding from Region Midtjyllands Strategiske forskningsmidler (English language “the Central Denmark Region’s Strategic Research Funds”. Additional applications for funding will be made. Current funding is sufficient for study initiation. New contributors will be reported as protocol changes (see the ‘Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}’ section) and mentioned on the trial website. All funding is handled by the financial department at the Prehospital Emergency Medical Services of the Central Denmark Region. Contributors have no influence on the trial, e.g. the design, conduct, results, or final manuscript."

"Trial registration European Union Clinical Trials (EUCT) number: 2022-502003-30-00 (authorised 06/12/2022), ClinicalTrials.gov number: NCT05703919 (released 02/02/2023), Universal trial number: U1111-1278-2162."